reports
- Kristof Samoy
Ekopak Partnership with unnamed infrastructure partner for WaaS develo...
Ekopak just announced a long term strategic partnership with an unnamed European infrastructure partner for the development of (large) WaaS projects. Many details are still unknown and management was not (yet) available for comments. The partnership introduces a minimum of €150m in off balance sheet funding over the next three years that will be deployed through dedicated asset companies financed with senior non recourse debt and majority equity from the infrastructure partner. As part of the pa...
- Guy Sips
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Wim Lewi
- Kristof Samoy
Fugro Hamburg declaration on new OFW investment pact and FY25 preview
Yesterday at a North Sea summit the Hamburg Declaration was signed by energy ministers from Belgium, Denmark, France, Germany, Ireland, Luxembourg, the Netherlands, Norway and the United Kingdom with Iceland joining as an observer. The governments agreed to work towards up to 100 GW of cross-border offshore wind capacity in the North Seas by 2050, while also advancing offshore renewable hydrogen as part of a more integrated regional energy system European governments committed to derisking offsh...
- Wim Lewi
Elia Group AI investment tsunami whips up TSO valuations
We upgrade our recommendation to Accumulate and raise our price target to €135.0 from €110.0 on multiple expansion over the next 6 to 12 months. We leave our EPS estimates for FY26-27 unchanged, but increase our price target to 22x FY27 EPS. Our previous target was based on 20x FY26 EPS, but we roll forward on a 10% higher multiple as the sentiment towards grid operators benefits from the “wall of money” into datacenters, while grid connection is the bottleneck. It can take years before the ROE ...
- Hilde Van Boxstael
- Lynn Hautekeete
- Thomas Couvreur
- Wim Lewi
- Thomas Couvreur
ING Increased estimates, but sector re-rate as main driver
Over the last few quarters ING's share price has appreciated significantly, mainly on the back of multiple expansion in the European banking sector. While ING doubled in value over the past 2 years, it's share price performance and multiple expansion is in line with its European peers. We increased our FY25-FY27 estimates and land on a new SOTP valuation of €26. Without a further increase in sector valuations, additional upside for ING is limited. We reiterate our Accumulate rating.
- Guy Sips
Biotalys Ending collaboration with Novonesis, new partnership with 21s...
Biotalys has entered into a strategic partnership with 21st.BIO to accelerate the production of Biotalys' protein-based biocontrol solutions. Biotalys indicated that this collaboration will leverage 21st.BIO's proprietary fermentation platform to support the production of Biotalys' AGROBODY agricultural biocontrol products at commercially competitive costs. We regret that Biotalys and Novonesis will conclude their collaboration (in line with the transition to this new agreement). Biotalys will...
- Guy Sips
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Lewi
- Mathijs Geerts Danau
Onward Medical Appoints Ali Kiboro as new CFO
Onward announced the appointment of a new CFO, Ali Kiboro. Mr. Kiboro brings more than 25 years of financial experience to Onward. He joins Onward from AliveDx where he served as Chief Financial Officer, leading the company's financial strategy, capital markets activities, and operational transformation. Prior to AliveDx, Ali held a variety of senior financial leadership roles at Quest Diagnostics and General Motors. Ali holds an MBA in Finance from The Wharton School and a Bachelor of Science i...
- Wim Lewi
Argan FY25 in line, aiming for 2 bond tranches, but no pressure
ARGAN reported FY25 EPRA net profit at €154.8m vs. our expectation of 153.3m. Argan already reported its annual rental income of €212.0m rental income in FY25, up 7% from FY24. Outlook FY26 guides for a Rental Income at 220m vs. 217m expected. The FY26 EPRA EPS is guided to approx. €6 vs. €6.04 expected. Argan plans 2 tranches of bond issues between April and October for a total between €500m and 700m. A “bridge to bond” has been agreed till November 2027 to relieve pressure (at a cost). The CF...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Thomas Couvreur
- Jacob Mekhael
Onward Medical Two additional BCI implants completed
Onward announced the successful 6th and 7th implants of its brain-computer interface (BCI) device in two additional spinal cord injury (SCI) patients, bringing the total number of human implants to seven. Onward's ARC-BCI effectively combines its proprietary implantable ARC-IM technology to affect movement and function with Clinatec's pioneering BCI device for thought-steered control, and we believe the joint technology could trigger a major step forward for patients suffering from spinal cord i...
- Lynn Hautekeete
Aedifica Road to merger unblocked
Aedifica obtained approval from the Belgian Competition Authority to proceed with its exchange offer on Cofinimmo. This approval is contingent on €300.0m of Belgian healthcare divestments to be executed over multiple years. The exchange period will open from 30 January to 2 March, contingent on FSMA approval of the prospectus. Given the significant overlap in the shareholder bases of Aedifica and Cofinimmo, and the formal support of Cofinimmo's board, we see a high likelihood of success. We upgr...
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Wim Lewi
- Jacob Mekhael
MaaT Pharma Randomises first patient in MaaT033 phase 2 trial in NSCLC
MaaT announced that the first patient has been randomised in the investigator sponsored multicenter phase 2 (IMMUNOLIFE) trial evaluating MaaT033 (microbiome therapy, oral capsule) in combination with cemiplimab (anti PD-1 antibody) in patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to PD-1/PD-L1 blockade following antibiotic (ATB) exposure and who present ATB-induced gut dysbiosis. Primary results after 1-year follow-up post-treatment could be expected in...
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Wim Lewi
- Kristof Samoy
Arcadis €175m SBB completed and FY25 preview
Arcadis has completed its share buyback program as of 16 January 2026. Since the launch of the program on 1 October 2025, the company repurchased a total of 4,575,796 ordinary shares for €175m, at an average price of €38.24. The shares acquired represent ca. 5% of the company's issued share capital and will be cancelled. We maintain our Hold.
- Kristof Samoy
Vopak Maersk not to invest in Vopak's brownfield in the port of Antwer...
Last Friday evening, Belgian newspaper De Tijd reported that Vioneo has halted plans for a €1.5bn green plastics plant in the Port of Antwerp. The project will instead be developed in China. Vioneo focuses on new technology to produce plastics without fossil feedstocks. The Maersk subsidiary had selected Antwerp in 2024 for its first large scale facility, designed to produce 300,000 tonnes of “green plastic” annually. The Vioneo plant was planned for the former Gunvor refinery site, a brownfield...
- Guy Sips
- Hilde Van Boxstael
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
- Guy Sips
Agfa Final resolution of price adjustment related to sale of Offset to...
In a press release -in which adherence to legal exactitude substantially compromised the clarity of the communication- Agfa announced the final resolution of the purchase price adjustment related to the 2022 sale of its Offset Solutions division to Aurelius. After contacting Agfa's management, it became clear that -following the independent expert's ruling- Agfa should receive €19.9m in cash within 15 business days, bringing the miss in total cash receipts from the original receivable of € 31...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.